140 related articles for article (PubMed ID: 7564224)
1. Liver transplantation in nine Spanish patients with tyrosinaemia type I.
Pérez-Cerdá C; Merinero B; Sanz P; Castro M; Gangoiti J; García MJ; Díaz M; Medina E; Ugarte M
J Inherit Metab Dis; 1995; 18(2):119-22. PubMed ID: 7564224
[No Abstract] [Full Text] [Related]
2. Liver transplantation in tyrosinaemia type I: the Groningen experience.
Wijburg FA; Reitsma WC; Slooff MJ; van Spronsen FJ; Koetse HA; Reijngoud DJ; Smit GP; Berger R; Bijleveld CM
J Inherit Metab Dis; 1995; 18(2):115-8. PubMed ID: 7564223
[No Abstract] [Full Text] [Related]
3. Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.
Schierbeek H; Beukeveld GJ; van Faassen H; van Spronsen FJ; Bijsterveld K; Venekamp-Hoolsema EE; Wolthers BG; Smit GP
J Inherit Metab Dis; 1993; 16(6):1034-40. PubMed ID: 8127053
[TBL] [Abstract][Full Text] [Related]
4. Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation.
van Spronsen FJ; Smit GP; Wijburg FA; Thomasse Y; Visser G; Heymans HS
J Inherit Metab Dis; 1995; 18(2):111-4. PubMed ID: 7564222
[No Abstract] [Full Text] [Related]
5. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
Barkaoui E; Debray D; Habès D; Ogier H; Bernard O
Arch Pediatr; 1999 May; 6(5):540-4. PubMed ID: 10370811
[TBL] [Abstract][Full Text] [Related]
6. Neonatal screen for hereditary tyrosinaemia type I.
Holme E; Lindstedt S
Lancet; 1992 Oct; 340(8823):850. PubMed ID: 1357267
[No Abstract] [Full Text] [Related]
7. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
8. Hematin therapy for the neurologic crisis of tyrosinemia.
Rank JM; Pascual-Leone A; Payne W; Glock M; Freese D; Sharp H; Bloomer JR
J Pediatr; 1991 Jan; 118(1):136-9. PubMed ID: 1986081
[No Abstract] [Full Text] [Related]
9. Urinary succinylacetone presence and delta-aminolaevulinic acid excretion in patients with type I tyrosinaemia during treatment.
Pronicka E; Mielniczuk Z; Rowińska E; Ksiazyk J; Szczygielska-Kozak M; Wieczorek E; Kulczycka H
Mater Med Pol; 1991; 23(2):136-8. PubMed ID: 1842600
[TBL] [Abstract][Full Text] [Related]
10. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.
Tuchman M; Freese DK; Sharp HL; Ramnaraine ML; Ascher N; Bloomer JR
J Pediatr; 1987 Mar; 110(3):399-403. PubMed ID: 3546650
[TBL] [Abstract][Full Text] [Related]
11. [Surgical and metabolic aspects of liver transplantation for tyrosinemia].
Bruneau N; St-Vil D; Luks FI; LaBerge JM; Bensoussan AL; Blanchard H
Ann Chir; 1993; 47(9):803-9. PubMed ID: 8141543
[TBL] [Abstract][Full Text] [Related]
12. Tyrosinaemia type I with normal levels of plasma tyrosine.
de Almeida IT; Leandro PP; Silva MF; Silveira C; da Silva A; de Sousa JS; Duran M
J Inherit Metab Dis; 1990; 13(3):305-7. PubMed ID: 2122090
[No Abstract] [Full Text] [Related]
13. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
[TBL] [Abstract][Full Text] [Related]
14. Succinylacetone and delta-aminolevulinic acid dehydratase in hereditary tyrosinemia: immunochemical study of the enzyme.
Sassa S; Fujita H; Kappas A
Pediatrics; 1990 Jul; 86(1):84-6. PubMed ID: 2359685
[TBL] [Abstract][Full Text] [Related]
15. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.
Bain MD; Purkiss P; Jones M; Bingham P; Stacey TE; Chalmers RA
Eur J Pediatr; 1990 Jun; 149(9):637-9. PubMed ID: 2373116
[TBL] [Abstract][Full Text] [Related]
16. Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem.
van Spronsen FJ; Berger R; Smit GP; de Klerk JB; Duran M; Bijleveld CM; van Faassen H; Slooff MJ; Heymans HS
J Inherit Metab Dis; 1989; 12 Suppl 2():339-42. PubMed ID: 2556611
[No Abstract] [Full Text] [Related]
17. Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction.
Kvittingen EA; Jellum E; Stokke O; Flatmark A; Bergan A; Sødal G; Halvorsen S; Schrumpf E; Gjone E
J Inherit Metab Dis; 1986; 9(2):216-24. PubMed ID: 3091928
[TBL] [Abstract][Full Text] [Related]
18. Neonatal and prenatal diagnosis of hereditary tyrosinaemia.
King GS; MacKenzie F; Pettit BR
Lancet; 1983 Jun; 1(8336):1279. PubMed ID: 6134070
[No Abstract] [Full Text] [Related]
19. Liver transplantation in two children with tyrosinaemia type I: biochemical aspects.
Riudor E; Ribes A; Lloret J; Friden J; Holme E; Jakobs C; Martinez Ibanez V
J Inherit Metab Dis; 1991; 14(3):281-4. PubMed ID: 1770775
[No Abstract] [Full Text] [Related]
20. Tyrosinaemia type Ia without excess of urinary succinylacetone.
Biasucci G; Giuffré B; La Grutta S; Riva E
J Inherit Metab Dis; 1993; 16(6):1056-7. PubMed ID: 8127063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
